CN107109405A - 具有生物可逆性和非生物可逆性基团的多核苷酸构建体 - Google Patents
具有生物可逆性和非生物可逆性基团的多核苷酸构建体 Download PDFInfo
- Publication number
- CN107109405A CN107109405A CN201580041889.0A CN201580041889A CN107109405A CN 107109405 A CN107109405 A CN 107109405A CN 201580041889 A CN201580041889 A CN 201580041889A CN 107109405 A CN107109405 A CN 107109405A
- Authority
- CN
- China
- Prior art keywords
- group
- optionally substituted
- alkyl
- polynucleotide construct
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CCCCN1*(C)CN*C1SS* Chemical compound CCCCN1*(C)CN*C1SS* 0.000 description 17
- KVSMFHFCEDYGEY-UHFFFAOYSA-N CC(C)(C)CC(C)=C1CCCCC1 Chemical compound CC(C)(C)CC(C)=C1CCCCC1 KVSMFHFCEDYGEY-UHFFFAOYSA-N 0.000 description 1
- UNXBOBALIDITOY-LWCMGDNJSA-N CC(C)SSc1[n+](C)(C)c(CC2[C@@H](CC(C)SSC(C)CCCO)C2)ccc1 Chemical compound CC(C)SSc1[n+](C)(C)c(CC2[C@@H](CC(C)SSC(C)CCCO)C2)ccc1 UNXBOBALIDITOY-LWCMGDNJSA-N 0.000 description 1
- QWAVNXZAQASOML-UHFFFAOYSA-N CC(COc1ccccc1)=O Chemical compound CC(COc1ccccc1)=O QWAVNXZAQASOML-UHFFFAOYSA-N 0.000 description 1
- ACQJOCJSOJAWMM-VXLYETTFSA-N CC/C=C/OCC(C(C1F)OP(N(C(C)C)C(C)C)OCCCCSSC(C)(C)CCC2OC2NCCOCCOCCOCCCOCCOCCOCCOCCOC)OC1N(C=CC(N1)=O)C1=O Chemical compound CC/C=C/OCC(C(C1F)OP(N(C(C)C)C(C)C)OCCCCSSC(C)(C)CCC2OC2NCCOCCOCCOCCCOCCOCCOCCOCCOC)OC1N(C=CC(N1)=O)C1=O ACQJOCJSOJAWMM-VXLYETTFSA-N 0.000 description 1
- ULIHJHSSPXPDIR-UHFFFAOYSA-N CCC(OCC(C(C1OC)OP(N(C(C)C)C(C)C)OCCc(cccc2)c2SSC(C)(C)C)OC1N(C1N=C(NC(COc2ccc(C(C)C)cc2)=O)N2)C=NC1C2=O)=C Chemical compound CCC(OCC(C(C1OC)OP(N(C(C)C)C(C)C)OCCc(cccc2)c2SSC(C)(C)C)OC1N(C1N=C(NC(COc2ccc(C(C)C)cc2)=O)N2)C=NC1C2=O)=C ULIHJHSSPXPDIR-UHFFFAOYSA-N 0.000 description 1
- GDDUGVPURCLITP-UHFFFAOYSA-N CCOCCc1c(C)cccc1NNC(C)(C)C Chemical compound CCOCCc1c(C)cccc1NNC(C)(C)C GDDUGVPURCLITP-UHFFFAOYSA-N 0.000 description 1
- KNYDIGUXZIOJAF-UHFFFAOYSA-N OC(c1ccc(C=O)cc1)O Chemical compound OC(c1ccc(C=O)cc1)O KNYDIGUXZIOJAF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3513—Protein; Peptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462009123P | 2014-06-06 | 2014-06-06 | |
| US62/009123 | 2014-06-06 | ||
| PCT/US2015/034749 WO2015188197A2 (en) | 2014-06-06 | 2015-06-08 | Polynucleotide constructs having bioreversible and non-bioreversible groups |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107109405A true CN107109405A (zh) | 2017-08-29 |
Family
ID=54767614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580041889.0A Pending CN107109405A (zh) | 2014-06-06 | 2015-06-08 | 具有生物可逆性和非生物可逆性基团的多核苷酸构建体 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20170114341A1 (https=) |
| EP (1) | EP3152308A4 (https=) |
| JP (1) | JP2017522046A (https=) |
| CN (1) | CN107109405A (https=) |
| AU (1) | AU2015269053A1 (https=) |
| CA (1) | CA2950960A1 (https=) |
| WO (1) | WO2015188197A2 (https=) |
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110959011A (zh) * | 2017-12-29 | 2020-04-03 | 苏州瑞博生物技术有限公司 | 缀合物及其制备方法和用途 |
| WO2020135673A1 (zh) * | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2020135581A1 (zh) * | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2020238763A1 (zh) * | 2019-05-24 | 2020-12-03 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| CN112390835A (zh) * | 2019-08-14 | 2021-02-23 | 苏州瑞博生物技术股份有限公司 | 肝靶向化合物及缀合物 |
| WO2021037205A1 (zh) * | 2019-08-29 | 2021-03-04 | 苏州瑞博生物技术股份有限公司 | 化合物和药物缀合物及其制备方法和用途 |
| WO2022161452A1 (zh) * | 2021-01-28 | 2022-08-04 | 南京桦冠生物技术有限公司 | 缀合物及其用途 |
| US11492620B2 (en) | 2017-12-01 | 2022-11-08 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
| CN115925586A (zh) * | 2022-11-01 | 2023-04-07 | 青岛蓝谷多肽生物医药科技有限公司 | 一种靶向psma的母体及其衍生物的制备方法 |
| US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
| CN116925160A (zh) * | 2023-09-15 | 2023-10-24 | 天津全和诚科技有限责任公司 | 一种GalNAc含糖环中间体及其制备方法 |
| US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
| US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
| WO2024093947A1 (zh) * | 2022-10-31 | 2024-05-10 | 大睿生物医药科技(上海)有限公司 | 向细胞内递送siRNA的前药 |
| US12084661B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| US12083142B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| WO2024222384A1 (zh) | 2023-04-26 | 2024-10-31 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| US12428642B2 (en) | 2017-12-01 | 2025-09-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, preparation method and use thereof |
| US12497622B2 (en) | 2019-05-22 | 2025-12-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| US12540323B2 (en) | 2019-05-22 | 2026-02-03 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| US12577565B2 (en) | 2019-05-24 | 2026-03-17 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| US12590304B2 (en) | 2019-05-22 | 2026-03-31 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201620526A (zh) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法 |
| US20180133327A1 (en) * | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| KR102713216B1 (ko) | 2015-06-25 | 2024-10-02 | 로스웰 엠이 아이엔씨. | 바이오분자 센서들 및 방법들 |
| AU2016365828A1 (en) * | 2015-12-08 | 2018-07-05 | Solstice Biologics, Ltd. | Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate |
| CN113985017A (zh) | 2016-01-14 | 2022-01-28 | 罗斯韦尔生物技术股份有限公司 | 分子传感器及相关方法 |
| CN109071212A (zh) | 2016-01-28 | 2018-12-21 | 罗斯韦尔生物技术股份有限公司 | 使用大规模分子电子传感器阵列测量分析物的方法和装置 |
| KR102763291B1 (ko) | 2016-01-28 | 2025-02-04 | 로스웰 엠이 아이엔씨. | 대량 병렬 ｄｎａ 시퀀싱 장치 |
| CA3053103A1 (en) | 2016-02-09 | 2017-08-17 | Roswell Biotechnologies, Inc. | Electronic label-free dna and genome sequencing |
| US10597767B2 (en) | 2016-02-22 | 2020-03-24 | Roswell Biotechnologies, Inc. | Nanoparticle fabrication |
| DK3429618T5 (da) | 2016-03-16 | 2024-09-16 | Amal Therapeutics Sa | Kombination af en immuncheckpoint-modulator og et kompleks som omfatter et cellepenetrerende peptid, en last og en tlr-peptidagonist til anvendelse i medicin |
| US9829456B1 (en) | 2016-07-26 | 2017-11-28 | Roswell Biotechnologies, Inc. | Method of making a multi-electrode structure usable in molecular sensing devices |
| EP3491150A4 (en) * | 2016-08-01 | 2020-03-11 | Roswell Biotechnologies, Inc | MODIFIED NUCLEOTIDE TRIPHOSPHATES FOR MOLECULAR ELECTRONIC SENSORS |
| JP2019532027A (ja) | 2016-08-17 | 2019-11-07 | ソルスティス バイオロジクス，リミティッド | ポリヌクレオチド構築物 |
| JP7249080B2 (ja) | 2016-08-23 | 2023-03-30 | ディセルナ ファーマシューティカルズ インコーポレイテッド | 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用 |
| DK3515476T3 (da) | 2016-09-21 | 2024-09-02 | Amal Therapeutics Sa | Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer |
| BR112019014282A2 (pt) * | 2017-01-10 | 2020-03-03 | Arrowhead Pharmaceuticals, Inc. | Agentes de rnai de antitripsina (aat) alfa-1, composições incluindo agentes de rnai de aat, e métodos de uso |
| CN110431148A (zh) | 2017-01-10 | 2019-11-08 | 罗斯威尔生命技术公司 | 用于dna数据存储的方法和系统 |
| CA3052140A1 (en) | 2017-01-19 | 2018-07-26 | Roswell Biotechnologies, Inc. | Solid state sequencing devices comprising two dimensional layer materials |
| MX2019012295A (es) * | 2017-04-14 | 2020-02-07 | Tollnine Inc | Polinucleotidos inmunomoduladores, conjugados de anticuerpos de los mismos y metodos para su uso. |
| US10508296B2 (en) | 2017-04-25 | 2019-12-17 | Roswell Biotechnologies, Inc. | Enzymatic circuits for molecular sensors |
| EP3615685B1 (en) | 2017-04-25 | 2025-02-19 | Roswell Biotechnologies, Inc | Enzymatic circuits for molecular sensors |
| EP3622086A4 (en) | 2017-05-09 | 2021-04-21 | Roswell Biotechnologies, Inc | BINDING PROBE CIRCUITS FOR MOLECULAR SENSORS |
| WO2019006455A1 (en) | 2017-06-30 | 2019-01-03 | Solstice Biologics, Ltd. | AUXILIARIES OF CHIRAL PHOSPHORAMIDITIS AND METHODS OF USE THEREOF |
| US11236334B2 (en) * | 2017-08-22 | 2022-02-01 | National University Corporation Nagoya University | Modified polynucleotide |
| CN111373049A (zh) | 2017-08-30 | 2020-07-03 | 罗斯威尔生命技术公司 | 用于dna数据存储的进行性酶分子电子传感器 |
| EP3694990A4 (en) | 2017-10-10 | 2022-06-15 | Roswell Biotechnologies, Inc. | METHODS, DEVICE AND SYSTEMS FOR AMPLIFICATION-FREE DNA DATA STORAGE |
| SI3684377T1 (sl) | 2017-10-20 | 2023-05-31 | Dicerna Pharmaceuticals, Inc. | Postopki zdravljenja okužbe s hepatitisom B |
| WO2019143621A1 (en) | 2018-01-16 | 2019-07-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting aldh2 expression |
| CN112041439A (zh) | 2018-02-14 | 2020-12-04 | 深度基因组学公司 | 用于威尔森病的寡核苷酸疗法 |
| WO2019217459A1 (en) | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| EP4512407A3 (en) | 2018-07-13 | 2025-09-24 | F. Hoffmann-La Roche AG | Oligonucleotides for modulating rtel1 expression |
| JP7536025B2 (ja) * | 2018-10-17 | 2024-08-19 | タラック セラピューティクス，インク． | 免疫調節性ポリヌクレオチドコンジュゲートと使用方法 |
| US11249941B2 (en) * | 2018-12-21 | 2022-02-15 | Palo Alto Research Center Incorporated | Exabyte-scale data storage using sequence-controlled polymers |
| CN113692444A (zh) | 2019-02-12 | 2021-11-23 | 迪克纳制药公司 | 用于抑制cyp27a1的表达的方法和组合物 |
| CA3135402A1 (en) | 2019-04-04 | 2020-10-08 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
| MX2021015003A (es) | 2019-06-06 | 2022-01-24 | Arrowhead Pharmaceuticals Inc | Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd). |
| WO2021067744A1 (en) | 2019-10-02 | 2021-04-08 | Dicerna Pharmaceuticals, Inc. | Chemical modifications of small interfering rna with minimal fluorine content |
| CN115175685B (zh) | 2019-12-09 | 2024-12-13 | 艾姆皮瑞克公司 | 用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸 |
| CN114828852A (zh) | 2019-12-24 | 2022-07-29 | 豪夫迈·罗氏有限公司 | 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合 |
| EP4081639A1 (en) | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv |
| BR112022017136A2 (pt) | 2020-02-28 | 2022-10-11 | Tallac Therapeutics Inc | Conjugação mediada por transglutaminase |
| AU2021236674B2 (en) | 2020-03-18 | 2025-03-06 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting ANGPTL3 expression |
| IL300283A (en) | 2020-08-04 | 2023-04-01 | Dicerna Pharmaceuticals Inc | Systemic administration of oligonucleotides |
| TW202221120A (zh) | 2020-08-04 | 2022-06-01 | 美商黛瑟納製藥公司 | 用於治療代謝症候群之組成物及方法 |
| CA3190794A1 (en) | 2020-08-05 | 2022-02-10 | Soren Ottosen | Oligonucleotide treatment of hepatitis b patients |
| KR102812602B1 (ko) | 2020-08-05 | 2025-05-28 | 다이서나 파마수이티컬, 인크. | Lpa 발현을 저해하기 위한 조성물 및 방법 |
| IL301940A (en) | 2020-10-08 | 2023-06-01 | Dicerna Pharmaceuticals Inc | Selective delivery of oligonucleotides to glial cells |
| WO2022081867A1 (en) * | 2020-10-14 | 2022-04-21 | North Carolina State University | Compositions and methods for drug delivery |
| US12084662B2 (en) | 2021-04-14 | 2024-09-10 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating PNPLA3 expression |
| CA3234478A1 (en) | 2021-11-11 | 2023-05-19 | Souphalone LUANGSAY | Pharmaceutical combinations for treatment of hbv |
| WO2023102469A2 (en) | 2021-12-01 | 2023-06-08 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for modulating apoc3 expression |
| US20250154191A1 (en) * | 2021-12-17 | 2025-05-15 | Liid Pharmaceuticals, Inc. | Oligonucleotide production method |
| EP4493570A2 (en) | 2022-03-16 | 2025-01-22 | Empirico Inc. | Galnac compositions for improving sirna bioavailability |
| KR20250005108A (ko) | 2022-04-15 | 2025-01-09 | 다이서나 파마수이티컬, 인크. | Scap 활성을 조절하기 위한 조성물 및 방법 |
| WO2024097310A2 (en) * | 2022-11-01 | 2024-05-10 | Impilo Therapeutics, Inc. | Targeted non-charged-nucleic acid (ncna) delivery and related tumor penetrating nanocomplexes |
| TW202430637A (zh) | 2022-11-16 | 2024-08-01 | 美商戴瑟納製藥股份有限公司 | Stat3靶向性寡核苷酸及其用途 |
| WO2025235911A2 (en) * | 2024-05-09 | 2025-11-13 | Wave Life Sciences Ltd. | Inhibin subunit beta e-related double stranded oligonucleotide compositions and methods relating thereto |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101490074A (zh) * | 2006-05-11 | 2009-07-22 | Isis药物公司 | 5’-修饰的双环核酸类似物 |
| US20120040459A1 (en) * | 2008-09-22 | 2012-02-16 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
| WO2014031575A1 (en) * | 2012-08-20 | 2014-02-27 | The Regents Of The University Of California | Polynucleotides having bioreversible groups |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120142763A1 (en) * | 2009-06-01 | 2012-06-07 | The Regents Of The University Of California | Nucleic acid delivery compositions and methods of use thereof |
| AU2014346658A1 (en) * | 2013-11-06 | 2016-06-02 | Solstice Biologics, Ltd. | Polynucleotide constructs having disulfide groups |
-
2015
- 2015-06-08 JP JP2017516650A patent/JP2017522046A/ja active Pending
- 2015-06-08 EP EP15803887.7A patent/EP3152308A4/en not_active Withdrawn
- 2015-06-08 AU AU2015269053A patent/AU2015269053A1/en not_active Abandoned
- 2015-06-08 CA CA2950960A patent/CA2950960A1/en not_active Abandoned
- 2015-06-08 US US15/315,608 patent/US20170114341A1/en not_active Abandoned
- 2015-06-08 CN CN201580041889.0A patent/CN107109405A/zh active Pending
- 2015-06-08 WO PCT/US2015/034749 patent/WO2015188197A2/en not_active Ceased
-
2020
- 2020-02-03 US US16/780,204 patent/US20200392498A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101490074A (zh) * | 2006-05-11 | 2009-07-22 | Isis药物公司 | 5’-修饰的双环核酸类似物 |
| US20120040459A1 (en) * | 2008-09-22 | 2012-02-16 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
| WO2014031575A1 (en) * | 2012-08-20 | 2014-02-27 | The Regents Of The University Of California | Polynucleotides having bioreversible groups |
Non-Patent Citations (1)
| Title |
|---|
| AFAF H EL-SAGHEER等: "Synthesis of Alkyne- and Azide-Modified Oligonucleotides and Their Cyclization by the CuAAC (Click) Reaction", 《CURRENT PROTOCOLS IN NUCLEIC ACID CHEMISTRY》 * |
Cited By (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12274752B2 (en) | 2017-12-01 | 2025-04-15 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
| US12083142B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| US12084661B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| US12428642B2 (en) | 2017-12-01 | 2025-09-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, preparation method and use thereof |
| US11492620B2 (en) | 2017-12-01 | 2022-11-08 | Suzhou Ribo Life Science Co., Ltd. | Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof |
| US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
| US11633482B2 (en) | 2017-12-29 | 2023-04-25 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
| CN116375774B (zh) * | 2017-12-29 | 2025-09-23 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
| CN116375774A (zh) * | 2017-12-29 | 2023-07-04 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
| CN110959011A (zh) * | 2017-12-29 | 2020-04-03 | 苏州瑞博生物技术有限公司 | 缀合物及其制备方法和用途 |
| CN110959011B (zh) * | 2017-12-29 | 2023-03-28 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
| US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
| US11896674B2 (en) | 2018-09-30 | 2024-02-13 | Suzhou Ribo Life Science Co., Ltd. | SiRNA conjugate, preparation method therefor and use thereof |
| CN112423794A (zh) * | 2018-12-28 | 2021-02-26 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2020135673A1 (zh) * | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2020135581A1 (zh) * | 2018-12-28 | 2020-07-02 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| US12496347B2 (en) | 2018-12-28 | 2025-12-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof |
| US12540323B2 (en) | 2019-05-22 | 2026-02-03 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| US12590304B2 (en) | 2019-05-22 | 2026-03-31 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| US12497622B2 (en) | 2019-05-22 | 2025-12-16 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| WO2020238763A1 (zh) * | 2019-05-24 | 2020-12-03 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| US12577565B2 (en) | 2019-05-24 | 2026-03-17 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| CN112390835A (zh) * | 2019-08-14 | 2021-02-23 | 苏州瑞博生物技术股份有限公司 | 肝靶向化合物及缀合物 |
| WO2021037205A1 (zh) * | 2019-08-29 | 2021-03-04 | 苏州瑞博生物技术股份有限公司 | 化合物和药物缀合物及其制备方法和用途 |
| CN113891892B (zh) * | 2019-08-29 | 2024-01-30 | 苏州瑞博生物技术股份有限公司 | 化合物和药物缀合物及其制备方法和用途 |
| CN113891892A (zh) * | 2019-08-29 | 2022-01-04 | 苏州瑞博生物技术股份有限公司 | 化合物和药物缀合物及其制备方法和用途 |
| WO2022161452A1 (zh) * | 2021-01-28 | 2022-08-04 | 南京桦冠生物技术有限公司 | 缀合物及其用途 |
| WO2024093947A1 (zh) * | 2022-10-31 | 2024-05-10 | 大睿生物医药科技(上海)有限公司 | 向细胞内递送siRNA的前药 |
| CN115925586A (zh) * | 2022-11-01 | 2023-04-07 | 青岛蓝谷多肽生物医药科技有限公司 | 一种靶向psma的母体及其衍生物的制备方法 |
| WO2024222384A1 (zh) | 2023-04-26 | 2024-10-31 | 上海麦科思生物医药有限公司 | 抗ptk7抗体及其用途 |
| US12534541B2 (en) | 2023-04-26 | 2026-01-27 | Mabcare Therapeutics | Anti-PTK7 antibody and uses thereof |
| CN116925160B (zh) * | 2023-09-15 | 2023-12-08 | 天津全和诚科技有限责任公司 | 一种GalNAc含糖环中间体及其制备方法 |
| CN116925160A (zh) * | 2023-09-15 | 2023-10-24 | 天津全和诚科技有限责任公司 | 一种GalNAc含糖环中间体及其制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015188197A2 (en) | 2015-12-10 |
| CA2950960A1 (en) | 2015-12-10 |
| US20200392498A1 (en) | 2020-12-17 |
| EP3152308A2 (en) | 2017-04-12 |
| US20170114341A1 (en) | 2017-04-27 |
| EP3152308A4 (en) | 2017-12-27 |
| AU2015269053A1 (en) | 2016-12-22 |
| JP2017522046A (ja) | 2017-08-10 |
| WO2015188197A3 (en) | 2016-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107109405A (zh) | 具有生物可逆性和非生物可逆性基团的多核苷酸构建体 | |
| US20160257961A1 (en) | Polynucleotide constructs having disulfide groups | |
| AU2023255025B2 (en) | Targeting ligands | |
| AU2013306006B2 (en) | Polynucleotides having bioreversible groups | |
| JP2019532027A (ja) | ポリヌクレオチド構築物 | |
| KR101707437B1 (ko) | 구아니딘 가교를 갖는 인공 뉴클레오시드 및 올리고뉴클레오티드 | |
| CN101506368B (zh) | 通过可逆的磷酸三酯电荷中和保护基转导运输核酸 | |
| CA3089276A1 (en) | Trialkyne linking agents and methods of use | |
| UA128250C2 (uk) | Ліганди інтегринів і їх застосування | |
| EP3386517A1 (en) | Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate | |
| WO2023045995A1 (en) | Multivalent Ligand Clusters with Diamine Scaffold for Targeted Delivery of Therapeutic Agents | |
| WO2024208249A1 (zh) | 5'-膦酸酯修饰的核苷类似物及其制备的寡核苷酸 | |
| Biscans et al. | Synthesis, binding, nuclease resistance and cellular uptake properties of 2′-O-acetalester-modified oligonucleotides containing cationic groups | |
| CN121127266A (zh) | 用于抑制中枢神经系统靶基因表达的多肽寡核苷酸缀合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170829 |
|
| WD01 | Invention patent application deemed withdrawn after publication |